Reuters logo
BRIEF-Inotek Pharmaceuticals says evaluating strategic alternatives
2017年7月7日 / 晚上8点16分 / 4 个月前

BRIEF-Inotek Pharmaceuticals says evaluating strategic alternatives

July 7 (Reuters) - Inotek Pharmaceuticals Corp:

* Inotek Pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update

* Inotek Pharmaceuticals Corp - company evaluating strategic alternatives

* Inotek Pharmaceuticals Corp - trabodenoson FDC demonstrated moderate IOP reduction over latanoprost alone when dosed in morning

* Inotek Pharmaceuticals Corp - ‍has engaged Perella Weinberg Partners as a financial advisor to assist with strategic review process​

* Inotek Pharmaceuticals Corp - trabodenoson FDC had comparable efficacy dosed in afternoon, and at day 56 over latanoprost alone

* Inotek Pharmaceuticals - addition of trabodenoson to latanoprost offered no clinically meaningful advantage in eye pressure reduction over latanoprost alone

* Inotek - based on these results and results for phase 3 matrx-1 monotherapy trial, co evaluating future clinical potential of trabodenoson Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below